Bone Material Comparison in Maxillary Sinus Augmentation
Primary Purpose
Alveolar Bone Resorption, Sequela, Tooth Extrusion
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Shefabone
Bio-Oss
Sponsored by
About this trial
This is an interventional treatment trial for Alveolar Bone Resorption focused on measuring Sinus pneumatization, Socket preservation, Sinus augmentation
Eligibility Criteria
Inclusion Criteria:
- 20 to 75 years of age
- at least one maxillary edentulous posterior site requiring maxillary sinus grafting and replacement with a dental implant.
Exclusion Criteria:
- current smokers/tobacco users
- are pregnant
- have active periodontal disease
- have uncontrolled diabetes
- have any autoimmune disease
- have kidney disease
- have liver disease
- are receiving radiation or chemotherapy
- have any type of radiographic periapical pathology such as a periapical abscess.
Sites / Locations
- University of Kentucky
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Experimental
Arm Label
Control Group
Test Group
Arm Description
Control group in this study will comprise of 10 subjects and will receive Bio-Oss xenograft bone material.
The test group in this study will comprise of 10 subjects and will receive Shefabone synthetic bone substitute.
Outcomes
Primary Outcome Measures
Bone Density - Limited View CBCT Measurements
Bone density will be measured by limited view CBCT radiography pre- and post-operatively.
Secondary Outcome Measures
Bone Quality
Bone quality will be measured using histomorphometric analysis.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04433117
Brief Title
Bone Material Comparison in Maxillary Sinus Augmentation
Official Title
Bone Quality and Quantity in the Maxillary Sinus Grafted With Xenograft or Synthetic Bone Substitute: A Radiographic and Histomorphometric Randomized Controlled Clinical Study
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
June 17, 2020 (Actual)
Primary Completion Date
February 14, 2023 (Actual)
Study Completion Date
March 1, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Mohanad Al-Sabbagh
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Hard and soft tissue deficiencies of an alveolar ridge arise as sequelae of tooth extraction when socket preservation is not applied. In addition, extraction of posterior maxillary teeth causes pneumatization of the maxillary sinus in relation to other fixed landmarks such as the teeth. These anatomic sinus limitations and alveolar bone deficiencies are the main challenges for dental implant placement. Different bone substitutes have been used to augment bone in pneumatized maxillary sinuses.
Scaffolding materials such as xenografts or synthetics substitutes have been proven to be a viable alternative.
Xenografts are obtained from nonhuman species and serve as a scaffold for the formation of new bone (osteoconduction). Histologic evaluation of maxillary sinuses grafted with xenografts revealed newly formed bone to be mostly woven bone with some remodeling to lamellar bone. These histologic findings reaffirm the osteoconductive ability of xenografts when used as the sole grafting material in maxillary sinus augmentation. Xenografts appear to be an effective method for maxillary sinus grafting and demonstrate limited resorption over time. Sinuses augmented with synthetic bone substitute (SBS) also appear to successfully integrate based on recent histomorphometric studies. Vascularization and trabecular bone formation in sinuses grafted with SBS has been previously demonstrated. One type of SBS includes porous granules of bioactive and resorbable silica-calcium phosphate nanocomposite (ShefaBone). ShefaBone grafts offer a novel alternative that can potentially unite the 3 salient bone-forming properties (osteoinduction, osteoconduction, and osteogenesis). ShefaBone has unique properties including: 1) bioactivity 2) bioresorbablility, and 3) allowing for the uptake of calcium ions from the physiological solution and releasing phosphate and silicate ions which aid in bone formation. A material with such properties will substitute bone in a more controlled and effective combination that can be obtained in many clinical situations, without the disadvantages found with autograft. ShefaBone has demonstrated successful regenerative properties for bony defects. To our knowledge, there is no reported clinical studies on the use of SCPC material to graft a pneumatized maxillary sinus. This aim of this current study is to compare SCPC to commonly used xenograft material in an augmented maxillary sinus.
Detailed Description
To assess the quality and quantity of the maxillary sinus bone prior to the placement of dental implants and subsequent restorations, approximately 20 patients will be randomly assigned to receive an augmentation of the maxillary sinus region using either Shefabone (synthetic bone) or Bio-Oss (xenograft).
With the use of pre-operative and post-operative limited view CBCT radiography, the maxillary sinus bone density will be assessed and compared between the individuals receiving Shefabone and the individuals receiving xenograft material.
Histomorphometric analysis will be used to assess, compare and contrast the quality and the quantity of the new vital bone cells generated when using these different graft materials.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alveolar Bone Resorption, Sequela, Tooth Extrusion
Keywords
Sinus pneumatization, Socket preservation, Sinus augmentation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled clinical trial. Entails 2 groups of subjects which will be randomly assigned. Group 1 will be the control group, and group 2 is test group.
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Control Group
Arm Type
Other
Arm Description
Control group in this study will comprise of 10 subjects and will receive Bio-Oss xenograft bone material.
Arm Title
Test Group
Arm Type
Experimental
Arm Description
The test group in this study will comprise of 10 subjects and will receive Shefabone synthetic bone substitute.
Intervention Type
Biological
Intervention Name(s)
Shefabone
Intervention Description
Silica-calcium phosphate composite.
Intervention Type
Biological
Intervention Name(s)
Bio-Oss
Other Intervention Name(s)
Bio-Oss by Geistlich
Intervention Description
Xenograft Bone substitute. Bone from animals.
Primary Outcome Measure Information:
Title
Bone Density - Limited View CBCT Measurements
Description
Bone density will be measured by limited view CBCT radiography pre- and post-operatively.
Time Frame
5 months
Secondary Outcome Measure Information:
Title
Bone Quality
Description
Bone quality will be measured using histomorphometric analysis.
Time Frame
5.5 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
20 to 75 years of age
at least one maxillary edentulous posterior site requiring maxillary sinus grafting and replacement with a dental implant.
Exclusion Criteria:
current smokers/tobacco users
are pregnant
have active periodontal disease
have uncontrolled diabetes
have any autoimmune disease
have kidney disease
have liver disease
are receiving radiation or chemotherapy
have any type of radiographic periapical pathology such as a periapical abscess.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mohanad Al-Sabbagh, DDS
Organizational Affiliation
University of Kentucky
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Kentucky
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40536
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Beneficial information for further research around the topic and/or information that may aid/benefit subjects or dentists in treatment may be shared.
Learn more about this trial
Bone Material Comparison in Maxillary Sinus Augmentation
We'll reach out to this number within 24 hrs